Table 2.
Associations of SF-6D utilities with symptoms, stratified by CD4 count, age, and race/ethnicity
| N | Utility of subjects with no symptoms | Utility change in symptomatic patients uncertain whether their symptoms are due to CART side effects (mean, 95% CI) | Utility change in symptomatic patients confident that their symptoms are due to CART side effects (mean, 95% CI) | |
|---|---|---|---|---|
| CD4 count (cells/μl) | ||||
| 0–49 | 94 | 0.66 | −0.00 (−0.06 to 0.07) | −0.03 (−0.10 to 0.05) |
| 50–199 | 365 | 0.73 | −0.07 (−0.10 to −0.04) | −0.05 (−0.09 to −0.02) |
| 200–349 | 486 | 0.72 | −0.04 (−0.07 to −0.01) | −0.04 (−0.07 to −0.01) |
| 350–499 | 435 | 0.74 | −0.07 (−0.10 to −0.04) | −0.07 (−0.10 to −0.04) |
| 500+ | 485 | 0.75 | −0.08 (−0.10 to −0.05) | −0.08 (−0.10 to −0.05) |
| Age (year) | ||||
| <35 | 90 | 0.78 | −0.06 (−0.12 to −0.01) | −0.03 (−0.10 to 0.04) |
| 35–44 | 462 | 0.75 | −0.06 (−0.09 to −0.03) | −0.07 (−0.10 to −0.04) |
| 45–54 | 924 | 0.72 | −0.06 (−0.08 to −0.04) | −0.06 (−0.08 to −0.04) |
| 55–64 | 421 | 0.73 | −0.07 (−0.10 to −0.04) | −0.05 (−0.08 to −0.02) |
| 65+ | 107 | 0.78 | −0.07 (−0.13 to −0.02) | −0.07 (−0.13 to −0.01) |
| Race/ethnicity | ||||
| Black | 1289 | 0.74 | −0.07 (−0.08 to −0.05) | −0.06 (−0.07 to −0.04) |
| White | 461 | 0.71 | −0.05 (−0.08 to −0.02) | −0.05 (−0.08 to −0.02) |
| Hispanic | 202 | 0.72 | −0.04 (−0.09 to 0.01) | −0.05 (−0.10 to 0.00) |
| Other | 52 | 0.74 | −0.11 (−0.20 to −0.02) | −0.10 (−0.20 to −0.00) |
| SF-12 score | ||||
| PCS | 2047 | 45.33 | −3.54 (−4.76 to −2.32) | −3.68 (−4.80 to −2.56) |
| MCS | 2047 | 32.16 | 1.13 (0.15 to 2.11) | 0.85 (−0.22 to 1.91) |
CART, combination antiretroviral therapy; CI, confidence interval; MCS, mental component score; PCS, physical component score.